BEAM
Beam Therapeutics Inc.NASDAQHealthcare$24.66+1.82%ClosedMarket Cap: $2.51B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.01
P/S
17.66
EV/EBITDA
-32.92
DCF Value
$-37.56
FCF Yield
-14.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-126.1%
Operating Margin
-274.6%
Net Margin
-57.2%
ROE
-7.3%
ROA
-5.4%
ROIC
-27.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $114.1M | 95.0% | $-17.4M | $244.3M | $2.33 | — |
| FY 2025 | $139.7M | 84.0% | $-383.7M | $-80.0M | $-0.81 | — |
| Q3 2025 | $9.7M | -1031.9% | $-126.8M | $-112.7M | $-1.10 | — |
| Q2 2025 | $8.5M | -1102.0% | $-120.2M | $-102.3M | $-1.00 | — |
| Q1 2025 | $7.5M | -1222.8% | $-119.3M | $-109.3M | $-1.24 | — |
| Q4 2024 | $30.1M | -237.4% | $-100.0M | $-90.4M | $-1.09 | — |
| FY 2024 | $63.5M | -478.7% | $-415.6M | $-376.7M | $-4.58 | — |
| Q3 2024 | $14.3M | -560.6% | $-106.5M | $-96.7M | $-1.17 | — |
| Q2 2024 | $11.8M | 100.0% | $-104.9M | $-91.1M | $-1.11 | — |
| Q1 2024 | $7.4M | -1044.6% | $-104.1M | $-98.7M | $-1.21 | — |
| Q4 2023 | $316.2M | 55.7% | $132.9M | $142.8M | $1.73 | — |
| FY 2023 | $377.7M | 100.0% | $-176.5M | $-132.5M | $-1.72 | — |